9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification

Key Takeaways Explain This Topic AI

The USPSTF (Grade B, ages 35–70 with overweight/obesity) and ADA (universal at age 35, or any age if BMI >=25 kg/m2 [>=23 kg/m2 in Asian Americans] plus >=1 cardiometabolic risk factor) recommend screening for prediabetes and type 2 diabetes every 3 years if normal.

Diagnostic thresholds for diabetes mellitus require meeting any one of four criteria: Fasting Plasma Glucose (FPG) >=126 mg/dL (7.0 mmol/L), 2-hour 75g Oral Glucose Tolerance Test (OGTT) >=200 mg/dL (11.1 mmol/L), Hemoglobin A1c >=6.5% (48 mmol/mol), or a random plasma glucose >=200 mg/dL (11.1 mmol/L) in the presence of classic hyperglycemic symptoms or hyperglycemic crisis.

In asymptomatic individuals, establishing a definitive diagnosis of diabetes requires two abnormal test results from either the same blood sample or two separate test samples; when two different screening tests are discordant, the test that was above the diagnostic threshold must be repeated, and diagnosis is based on the confirmed result.

Hemoglobin A1c accuracy depends on normal erythrocyte kinetics: conditions shortening erythrocyte lifespan (hemolysis, hemodialysis, acute blood loss, recent transfusion, erythropoietin, pregnancy) cause falsely low A1c, whereas lengthened lifespan (severe iron deficiency anemia, splenectomy) causes falsely high A1c; when assay interference occurs, plasma glucose criteria must be used.

The landmark Diabetes Prevention Program (DPP) demonstrated that intensive lifestyle intervention (achieving >=7% body weight reduction and >=150 minutes/week of moderate physical activity) reduced 3-year type 2 diabetes incidence by 58% (71% in adults aged >=60), significantly outperforming metformin therapy (31% reduction; most effective in patients aged <60, BMI >=35 kg/m2, or with a history of gestational diabetes).

Last updated: September 2026

Pathophysiology of Dysglycemia and the Clinical Imperative for Screening

Type 2 diabetes mellitus (T2D) is a progressive cardiometabolic disorder characterized by the twin pathophysiologic defects of peripheral insulin resistance (predominantly in skeletal muscle, liver, and adipose tissue) and progressive pancreatic beta-cell secretory dysfunction . The disease develops across a prolonged, insidious continuum spanning several years to decades. During the early stages of dysglycemia, pancreatic beta cells hypersecrete insulin to compensate for tissue resistance, maintaining normal plasma glucose concentrations at the expense of chronic hyperinsulinemia. Over time, progressive beta-cell exhaustion, exacerbated by glucotoxicity, lipotoxicity, and local islet amyloid polypeptide deposition, leads to postprandial glycemic excursions ( impaired glucose tolerance [IGT] ) and unsuppressed hepatic gluconeogenesis during fasting ( impaired fasting glucose [IFG] ), ultimately culminating in overt type 2 diabetes.

Critically, microvascular injury (diabetic retinopathy, microalbuminuria, distal symmetric polyneuropathy) and macrovascular atherosclerosis (coronary artery disease, ischemic stroke, peripheral artery disease) develop silently during the subclinical prediabetes phase long before clinical diagnosis. At the time of conventional symptomatic presentation, patients have frequently experienced dysglycemia for 4 to 7 years, and up to 20% already manifest documented diabetic retinopathy on fundoscopy. Systematic screening identifies individuals in the reversible prediabetic stage or early asymptomatic diabetic stage, enabling targeted interventions that halt microvascular damage, preserve beta-cell reserve, and reduce cardiovascular morbidity.

Screening Guidelines: USPSTF Grade B vs. ADA Standards of Care

Primary care physicians must navigate two primary evidence-based screening frameworks: the USPSTF guidelines and the American Diabetes Association (ADA) Standards of Care .

Comparison of USPSTF and ADA Screening Recommendations

Guideline Organization Target Population for Screening Age Threshold Weight / BMI Cutoff Recommended Testing Interval

USPSTF (2021 Update, Grade B) Asymptomatic non-pregnant adults with overweight or obesity Ages 35 to 70 years BMI >= 25 kg/m2 (or >= 23 kg/m2 in Asian Americans) Every 3 years if results are normal; annual if prediabetes is identified

ADA Standards of Care Universal screening for all asymptomatic adults Age >= 35 years Universal at age 35 regardless of BMI or risk factors Every 3 years if results are normal; annual if prediabetes is identified

ADA Standards of Care Risk-based screening in asymptomatic adults Any age (including youth) BMI >= 25 kg/m2 (or >= 23 kg/m2 in Asian Americans) PLUS >= 1 risk factor Every 1 to 3 years depending on risk profile

Critical Clinical Caveat: The Asian American BMI Threshold

A vital board exam concept is the reduced BMI cutoff for individuals of Asian ancestry . Substantial epidemiological data prove that Asian populations develop visceral adiposity, hepatic steatosis, metabolic syndrome, and type 2 diabetes at significantly lower body mass index levels and younger ages than individuals of European ancestry. Consequently, both the ADA and the USPSTF formally mandate that the definition of overweight triggering metabolic screening in Asian Americans is BMI >= 23.0 kg/m2 (rather than the standard >= 25.0 kg/m2). Clinicians who rely on standard BMI thresholds fail to diagnose dysglycemia in nearly one-third of Asian American adults.

ADA Risk Factors Triggering Early Screening in Overweight Individuals of Any Age

In an individual with a BMI >= 25 kg/m2 (or >= 23 kg/m2 in Asian Americans), metabolic screening should be initiated immediately at any age if at least one of the following risk criteria is present:

First-degree relative with diabetes (parent, sibling, or child).

High-risk race or ethnicity : African American, Hispanic / Latino American, American Indian / Alaska Native, Asian American, or Native Hawaiian / Pacific Islander.

History of clinical cardiovascular disease (prior MI, stroke, TIA, stable angina, or peripheral artery disease).

Hypertension : Blood pressure >= 130/80 mm Hg or current treatment with antihypertensive medications.

Atherogenic Dyslipidemia : HDL cholesterol < 35 mg/dL (<0.90 mmol/L) and/or fasting triglyceride level > 250 mg/dL (>2.82 mmol/L).

Polycystic Ovary Syndrome (PCOS) : Promotes profound hyperinsulinemic insulin resistance.

Physical Inactivity : Sedentary occupational and recreational lifestyle.

Conditions associated with severe insulin resistance : Severe obesity, acanthosis nigricans.

History of Gestational Diabetes Mellitus (GDM) : Mandates formal 75g OGTT at 4 to 12 weeks postpartum, followed by lifelong screening at least every 3 years.

Pre-existing Prediabetes : Prior A1c 5.7%–6.4%, impaired fasting glucose, or impaired glucose tolerance warrants annual screening.

People living with HIV : Due to antiretroviral therapy (protease inhibitors, INSTIs) and chronic immune activation.

Master Diagnostic Matrix: Fasting Glucose, OGTT, and HbA1c

Four distinct laboratory modalities are recognized to establish glycemic status. With the exception of random plasma glucose in a symptomatic patient, all screening tests require venous plasma measurements in an accredited laboratory:

Diagnostic Thresholds for Normoglycemia, Prediabetes, and Diabetes Mellitus

Diagnostic Category Fasting Plasma Glucose (FPG) 2-Hour 75g Oral Glucose Tolerance Test (OGTT) Hemoglobin A1c (NGSP-Certified) Random Plasma Glucose

Normal Glycemia < 100 mg/dL (<5.6 mmol/L) < 140 mg/dL (<7.8 mmol/L) < 5.7% (<39 mmol/mol) N/A (Normoglycemic range)

Prediabetes 100–125 mg/dL (5.6–6.9 mmol/L) (Impaired Fasting Glucose, IFG) 140–199 mg/dL (7.8–11.0 mmol/L) (Impaired Glucose Tolerance, IGT) 5.7%–6.4% (39–47 mmol/mol) (High Risk for Diabetes) N/A (Does not define prediabetes)

Diabetes Mellitus >= 126 mg/dL (>= 7.0 mmol/L) (Fasting >= 8 hours) >= 200 mg/dL (>= 11.1 mmol/L) (75g anhydrous glucose load) >= 6.5% (>= 48 mmol/mol) (DCCT-aligned assay) >= 200 mg/dL (>= 11.1 mmol/L) WITH classic symptoms

• Detailed Characteristics of Glycemic Diagnostic Modalities
• 1. Fasting Plasma Glucose (FPG)

Requirements : No caloric intake for at least 8 hours prior to venipuncture.

Physiologic Meaning : Reflects basal endogenous glucose production, which is predominantly governed by hepatic gluconeogenesis and glycogenolysis under the control of basal hepatic insulin sensitivity.

Clinical Characteristics : Inexpensive, universally accessible, and highly reproducible. Disadvantages include the requirement for strict overnight fasting and substantial intra-individual day-to-day biological variability (coefficient of variation ~5%–8%).

2. 2-Hour 75g Oral Glucose Tolerance Test (OGTT)

Requirements : Patient consumes a standardized 75-gram anhydrous glucose solution dissolved in water over 5 minutes following an overnight fast; venous plasma glucose is measured precisely at the 2-hour mark. Patient must ingest an unrestricted carbohydrate diet (>= 150 g/day) for 3 days prior.

Physiologic Meaning : Assesses peripheral glucose disposal under acute physiological challenge, reflecting peripheral skeletal muscle insulin sensitivity and early phase pancreatic beta-cell release.

Clinical Characteristics : The most sensitive diagnostic test for identifying early prediabetes and occult postprandial hyperglycemia. Disadvantages include inconvenience (requiring a 2-hour office stay), poor patient palatability (nausea), and higher laboratory cost.

3. Hemoglobin A1c (Glycated Hemoglobin)

Requirements : No fasting required. Must be analyzed in an accredited laboratory using a method that is certified by the National Glycohemoglobin Standardization Program (NGSP) and standardized to the Diabetes Control and Complications Trial (DCCT) reference assay. Point-of-care (fingerstick) A1c assays are approved for monitoring therapeutic response in clinic, but are not approved for initial diagnostic screening unless specifically certified by the FDA for diagnostic use.

Physiologic Meaning : Measures the non-enzymatic, irreversible ketoamine glycation of the N-terminal valine on the beta chain of hemoglobin A. It reflects weighted mean ambient plasma glycemia over the preceding 120 days (the normal erythrocyte lifespan), with approximately 50% of the value determined by ambient glycemia in the preceding 30 days.

Clinical Characteristics : Excellent pre-analytic stability, high clinical convenience (can be drawn non-fasting at any time of day), and low day-to-day intra-individual variation (<2%). Disadvantages include higher test cost, lower sensitivity at diagnostic margins, and susceptibility to erroneous values in patients with hematologic, renal, or hepatic disorders.

4. Random Plasma Glucose

Requirements : Venous blood draw without regard to time since the last meal.

Diagnostic Utility : A random plasma glucose >= 200 mg/dL is diagnostic of diabetes only when accompanied by classic signs and symptoms of hyperglycemia —specifically polyuria (osmotic diuresis), polydipsia (hyperosmolar thirst), polyphagia, unexplained rapid weight loss, or lethargy—or in the setting of acute hyperglycemic crises ( Diabetic Ketoacidosis [DKA] or Hyperosmolar Hyperglycemic State [HHS] ). In an asymptomatic individual, a random glucose >= 200 mg/dL is not diagnostic and mandates formal confirmation with fasting glucose, 75g OGTT, or A1c.

The Confirmation Mandate and Algorithmic Management of Discordant Results

A cardinal principle tested on board examinations is the Confirmation Rule :

The Confirmation Rule : In an asymptomatic patient , a single abnormal screening test result is never sufficient to diagnose diabetes mellitus. The diagnosis strictly requires two abnormal test results from either the same blood sample or two separate test samples.

Practical Confirmation Algorithms

Two Tests Drawn Concurrently (Same Blood Sample) :

If a clinician orders an FPG and an A1c on the same day, and both are elevated above the diagnostic threshold (e.g., FPG 132 mg/dL and A1c 6.8%), the diagnosis of diabetes mellitus is confirmed immediately . No further testing is required.

If both tests are in the prediabetic range (e.g., FPG 112 mg/dL and A1c 6.0%), prediabetes is confirmed.

Sequential Testing (Two Separate Blood Samples) :

If only a single test was initially ordered and returns abnormal (e.g., screening A1c 6.7%), the clinician must obtain a second confirmatory test on a subsequent day. The clinician may repeat the original test (repeat A1c) or order an alternative test (FPG). If the second test is also abnormal above the diagnostic threshold, diabetes is confirmed.

Managing Discordant Test Results :

A frequent clinical conundrum occurs when two different tests are discordant (e.g., A1c is 6.6% [diabetic range], but FPG is 114 mg/dL [prediabetic range]).

Guideline Rule : When two different tests are discordant, the clinician must repeat the test that was ABOVE the diagnostic threshold (in this scenario, repeat the A1c). If the repeated test remains above the diagnostic threshold, the diagnosis of diabetes is established.

Rationale : Different tests reflect distinct physiologic compartments (FPG reflects hepatic basal output, whereas A1c reflects integrated 3-month exposure). Repeating the elevated test confirms analytical accuracy and prevents false-negative misclassification.

Diagnostic Pitfalls: Confounders and Artifacts of Hemoglobin A1c Measurement

Because Hemoglobin A1c is mathematically dependent on both the ambient glucose concentration and the lifespan of circulating red blood cells (RBCs) , any physiological, genetic, or pharmacological condition that alters erythrocyte survival, glycation kinetics, or hemoglobin composition produces spurious A1c values that do not reflect true ambient glycemia:

Pathophysiologic Conditions Altering Hemoglobin A1c Independent of Glycemia

Confounding Clinical Condition Pathophysiologic Mechanism Impact on HbA1c Diagnostic Action Required

Hemolytic Anemia (Autoimmune, hereditary spherocytosis, mechanical valves) Shortened RBC survival; premature erythrocyte destruction decreases exposure to ambient glucose Falsely Low Rely exclusively on FPG, 2-hr OGTT, or continuous glucose monitoring (CGM)

Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency Chronic or episodic hemolysis shortens average red cell lifespan Falsely Low Measure FPG or 2-hr OGTT; do not use A1c to diagnose or monitor

End-Stage Renal Disease (ESRD) / Hemodialysis Erythrocyte fragility, shortened survival, and repeated blood loss on circuit; high proportion of young reticulocytes Falsely Low Use glycated albumin, continuous glucose monitoring, or fingerstick glucose profiles

Erythropoietin (EPO) Therapy Rapid stimulation of erythropoiesis floods peripheral circulation with non-glycated young reticulocytes Falsely Low Rely on plasma glucose criteria during active ESA therapy

Recovery from Acute Blood Loss or Recent Transfusion Massive reticulocytosis (after hemorrhage) or donor RBCs (transfusion) dilute glycated cells Falsely Low Defer A1c for at least 3 months following transfusion or acute hemorrhage

Pregnancy (2nd and 3rd Trimesters) Increased erythrocyte turnover and hemodilution reduce circulating RBC age Falsely Low Utilize oral glucose tolerance testing (75g or 100g OGTT) for screening and diagnosis

Severe Iron Deficiency Anemia (IDA) Decreased erythropoiesis prolongs circulation time of aging RBCs, permitting prolonged glycation Falsely High Treat iron deficiency; recheck A1c after hematologic recovery or use FPG/OGTT

Vitamin B12 or Folate Deficiency Anemia Impaired DNA synthesis causes ineffective erythropoiesis and prolonged circulating RBC lifespan Falsely High Replete micronutrient stores; rely on plasma glucose criteria in the interim

Post-Splenectomy / Asplenia Absence of splenic clearance allows senescent, heavily glycated erythrocytes to persist in circulation Falsely High Rely on FPG or 2-hr OGTT

Advanced Uremia (Pre-Dialysis CKD) Urea decomposes into cyanate, forming carbamylated hemoglobin that cross-reacts on legacy ion-exchange HPLC Falsely High (on older assays) Use NGSP-certified boronate affinity chromatography or immunoassay, or measure FPG

Severe Hyperbilirubinemia / Hypertriglyceridemia Optical and chromatographic assay interference during spectrophotometric detection Falsely High or Low Use alternative enzymatic or boronate affinity assays, or FPG

Hemoglobin Variants and Alternative Glycemic Biomarkers

Hemoglobinopathies (Sickle Cell Trait [HbAS], Hemoglobin C Trait [HbAC], Hemoglobin E Trait [HbAE]) : In individuals with heterozygous hemoglobin traits, erythrocyte lifespan is generally normal. Most modern NGSP-certified immunoassay and boronate affinity chromatography assays measure HbA1c accurately without interference. However, older cation-exchange HPLC assays produce inaccurate readings. If assay interference is reported by the laboratory, or in homozygous states (HbSS, HbCC) where hemolysis is prominent, A1c must not be utilized ; clinicians must rely on fasting plasma glucose or oral glucose tolerance testing.

Fructosamine (Glycated Serum Protein) : Measures non-enzymatic glycation of total serum proteins (predominantly albumin). Because albumin has a circulating half-life of approximately 14 to 20 days, fructosamine reflects glycemic control over the preceding 2 to 3 weeks . It is highly useful in patients with hemoglobinopathies, hemolytic anemias, or rapidly shifting glycemic control during pregnancy. Limitation : Fructosamine is invalidated by states of abnormal protein turnover (nephrotic syndrome, cirrhosis, protein-losing enteropathy).

1,5-Anhydroglucitol (1,5-AG) : A validated biomarker of short-term (1 to 2 weeks) glycemic excursions and postprandial glycemic spikes.

Evidence-Based Prediabetes Interventions: The Landmark Diabetes Prevention Program (DPP)

An individual diagnosed with prediabetes faces a 5% to 10% annual risk of progression to overt type 2 diabetes, with up to 70% developing diabetes within their lifetime. The landmark Diabetes Prevention Program (DPP) , a randomized multicenter clinical trial involving 3,234 high-risk participants with impaired glucose tolerance and elevated fasting glucose, definitively established the efficacy of preventive interventions over an average 2.8-year follow-up:

• DPP Interventions and Outcome Results ┌─────────────────────────────────────┐
• │ DPP Study Cohort (N=3,234) │
• │ (Impaired Glucose Tolerance, IGT) │
• └──────────────────┬──────────────────┘
• │
• ┌───────────────────────┼───────────────────────┐
• ▼ ▼ ▼
• ┌─────────────────────────┐ ┌─────────────────────────┐ ┌─────────────────────────┐
• │ Intensive Lifestyle │ │ Metformin Arm │ │ Placebo Arm │
• │ (16 Lessons) │ │ (850 mg Twice Daily) │ │ (Standard Care) │
• └────────────┬────────────┘ └────────────┬────────────┘ └────────────┬────────────┘
• │ │ │

Goals Achieved: Outcome: Outcome:

• >=7% Body Weight Loss • 31% Diabetes Risk • Reference Baseline
• >=150 min/wk Activity Reduction Progression Rate
• Outcome: • Most effective in: (11% per year)
• 58% Diabetes Risk - Age 25-59 years
• Reduction - BMI >=35 kg/m2
• 71% Risk Reduction - Prior Gestational DM
• in Age >=60 years
• Critical Takeaways from the DPP

Intensive Lifestyle Intervention : The intensive lifestyle program achieved an extraordinary 58% relative reduction in the incidence of type 2 diabetes compared to placebo. The primary targets were achieving and maintaining at least 7% loss of initial body weight via a low-calorie, low-fat diet, combined with at least 150 minutes per week of moderate-intensity physical activity (such as brisk walking).

Age Interaction : The efficacy of lifestyle intervention increased with patient age: participants aged >= 60 years achieved a 71% risk reduction .

Metformin Chemoprevention : Metformin (850 mg orally twice daily) produced an overall 31% relative reduction in diabetes incidence compared to placebo.

Metformin Subgroup Efficacy : Metformin was nearly as effective as lifestyle intervention in specific demographic cohorts: individuals aged 25 to 59 years , individuals with severe obesity ( BMI >= 35 kg/m2 ), and women with a documented personal history of gestational diabetes mellitus (where metformin achieved a ~50% risk reduction).

ADA Clinical Practice Recommendations for Prediabetes

First-Line Therapy : All patients with prediabetes must be referred to an intensive, CDC-recognized National Diabetes Prevention Program (NDPP) targeting >= 7% weight loss and >= 150 minutes/week of moderate exercise.

Metformin Chemoprevention Indications : The ADA recommends that metformin pharmacotherapy should be considered for the prevention of type 2 diabetes in patients with prediabetes who meet any of the following:

• Body Mass Index >= 35 kg/m2
• Age < 60 years
• History of Gestational Diabetes Mellitus (GDM)
• Progressively rising HbA1c despite intensive lifestyle interventions

Surveillance : Patients with documented prediabetes must undergo annual glycemic testing (A1c or FPG) to detect transition to overt diabetes.

Board Exam Traps & High-Yield Clinical Pearls

Exam Trap — Atypical Diabetes Presentations (MODY vs. LADA) :

MODY (Maturity-Onset Diabetes of the Young) : Monogenic, autosomal dominant non-insulin-dependent diabetes presenting in non-obese young adults (typically <25 years) with strong multigenerational family history. Caused by single-gene mutations (most commonly HNF1A [MODY 3] or GCK [MODY 2]). Autoantibodies (anti-GAD65, anti-IA2, anti-ZnT8) are negative . MODY 3 patients exhibit marked sensitivity to low-dose oral sulfonylureas and do not require insulin.

LADA (Latent Autoimmune Diabetes in Adults) : Autoimmune "Type 1.5" diabetes presenting in lean or normal-weight adults aged 30 to 50 years, frequently misdiagnosed as T2D. Patients initially respond to oral agents but progress rapidly to absolute insulin dependence within 6 to 12 months. Positive for anti-GAD65 autoantibodies and low fasting C-peptide.

Exam Pearl — Metformin Renal Dosing and Safety Thresholds :

Obtain baseline serum creatinine and calculate estimated GFR (eGFR) prior to initiation.

eGFR >= 60 mL/min/1.73m2 : Full dosing permitted (maximum 2000–2550 mg/day); monitor renal function annually.

eGFR 45–59 mL/min/1.73m2 : Full dosing permitted; monitor renal function every 3 to 6 months.

eGFR 30–44 mL/min/1.73m2 : Do not initiate metformin. If already taking metformin, reduce dose by 50% (maximum 1000 mg/day) and monitor renal function every 3 months.

eGFR < 30 mL/min/1.73m2 : Absolute contraindication ; discontinue metformin immediately due to the risk of fatal metformin-associated lactic acidosis (MALA).

Vitamin B12 Deficiency : Long-term metformin use impairs intestinal calcium-dependent absorption of the B12-intrinsic factor complex; monitor serum vitamin B12 levels every 2 to 3 years or upon onset of peripheral neuropathy or macrocytic anemia.

Loading diagram... Type 2 Diabetes Screening, Diagnostic Confirmation & Prediabetes Management Pathway